Anti-Glycoprotein [MR78]

Absolute Antibody

Anti-Glycoprotein [MR78]

9

This antibody recognizes a GP1 epitope conserved across the filovirus family, which likely represents the binding site of their NPC1 receptor. This antibody also blocks binding of the NPC1 domain C to MARV GP. This antibody was also capable of reacting wi

The binding specificity of the hybridoma supernatants for MARV glycoprotein was done using ELISA. ELISA was also performed to check whether the original Fab version of this antibody cross reacted with Ebola virus GP receptor-binding site. This antibody was also found to neutralize vesicular stomatitis virus/Marburg glycoprotein recombinant protein (VSV/GP-Uganda) and MARV-Uganda in a neutralization assay (PMID: 25723164). The crystal structure of this antibody in combination with Marburg virus Gp and Ebola virus GP demonstrates that the MR78 antibody recognizes a similar site on both MARV and EBOV. The epitope is a highly conserved hydrophobic trough revealed at the top of the EBOV GP1 core, after removal of the glycan cap by proteolytic cleavage in the endosome (PMID: 25723165). This antibody was recombinantly produced in tobacco (N. benthamiana) and was used in the in vivo therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates like guinea pigs. This antibody was reported to provide 100% protection and virus could not be detected in plasma sampled 7 dpi in animals treated with MR78-N (PMID: 28381540). MR78 fails to neutralize VSVs bearing GPCL derived from any species other than MARV (PMID: 26908579).

ELISA, Neutralisation/Blocking

Research Use Only

Monoclonal

MR78

Human

This reformatted human antibody was made using the variable domain sequences of the original Human Fab format for improved compatibility with existing reagents assays and techniques.

Virus

-20°C,2°C to 8°C

12352203